PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit writes about the key takeaways from the ASCO 2025 Annual ...

Puma Biotechnology remains undervalued despite steady neratinib sales and a promising, though early-stage, pipeline. Learn ...

Two recent studies from Dr. Sita Kugel’s lab at Fred Hutch Cancer Center identify a key biological signature that not only ...

Daraxonrasib has received breakthrough therapy designation from the FDA for KRAS G12+, previously treated, metastatic ...

Pancreatic cystic tumors: Pancreatic cysts (also called intraductal papillary mucinous neoplasms) may become precancerous or cancerous based on their location within the pancreas. Diet: Eating an ...

Exelixis stock shines with 36% CABOMETYX sales growth, promising zanzalintinib market expansions, and raised 2025 guidance.

Background and aim The International Cancer of the Pancreas Screening Consortium met in 2018 to update its consensus recommendations for the management of individuals with increased risk of pancreatic ...

“It came as a surprise that our approach works so well,” Lu said. In preclinical (non-human) studies, the vaccine completely ...

Gianna Moore fought a rare form of cancer, but didn't let it diminish her love for soccer. She is The Enquirer's 2025 Courage ...

New trial data reveals atebimetinib combined with gemcitabine/nab-paclitaxel significantly improves survival rates in ...

The FDA has granted Fast Track designation to nadunolimab to treat patients with previously untreated metastatic pancreatic ductal adenocarcinoma.

A new research paper was published in Volume 16 of Oncotarget on June 10, 2025, titled "Exceptional responders to immunotherapy in pancreatic cancer: A multi-institutional case series of a rare ...